Current Colorectal Cancer Reports

, Volume 9, Issue 4, pp 326–330

How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?

Translational Colorectal Oncology (Y Jiang, Section Editor)

DOI: 10.1007/s11888-013-0183-4

Cite this article as:
Tsvetkova, E. & Asmis, T.R. Curr Colorectal Cancer Rep (2013) 9: 326. doi:10.1007/s11888-013-0183-4


Colorectal cancer is the fourth commonest cancer worldwide. The survival rate is suboptimal for patients with metastatic disease. The introduction of anti-epidermal growth factor receptor (EGFR) antibodies has remarkably improved clinical outcomes. Two monoclonal antibodies targeting EGFR and one multikinase inhibitor have been approved by the FDA and Health Canada for the treatment of metastatic colorectal cancer; however, only about 10 % of patients respond to this treatment. Having wild-type KRAS is necessary but not sufficient to derive benefit from EGFR inhibition. Interestingly, patients with certain mutations such as p.G13D represent a cetuximab-sensitive subtype of KRAS mutant metastatic colorectal cancer. A few biomarkers have been identified, but we still do not know the best way to administer drugs. In this article we review the clinical data and expert opinions and summarize the recommendations.


Colorectal cancerKRASBRAFCetuximabPanitumumabRegorafenibAnti-epidermal growth factor receptor therapy

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.The Ottawa Hospital Cancer CentreUniversity of OttawaOttawaCanada